ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutic...(de but are not limited to ProMetic's abi...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
Date:12/9/2008
de, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
'/>"/>
| SOURCE Prometic Life Sciences Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. ProMetic to present at Merriman Curhan Fords Investor Summit 2008 on September 16th
2. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
3. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
4. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
5. Prometic provides information for its Annual and Special Meeting of Shareholders
6. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
7. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
8. Prometic to present at the American Chemical Society
9. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
10. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
11. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
Post Your Comments:
Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 2CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 3Dendreon Announces Proposed Public Offering of Common Stock 2Dendreon Announces Proposed Public Offering of Common Stock 3
[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain[0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products[0] CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner [0] Dendreon Announces Proposed Public Offering of Common Stock
Other Biology Technology:Scalable performance monitoring software draws grant from Intel 2Tech Digest (11/10/2004) 2
Breaking Biology News(10 mins):The pitch of blue whale songs is declining around the world, scientists discover 2The pitch of blue whale songs is declining around the world, scientists discover 3MSU research may lead to new ways to control honeybee parasite 2Univalor and Cognitive Sensing Inc to commercialize 4 University of Montreal discoveries 62128 1Univalor and Cognitive Sensing Inc to commercialize 4 University of Montreal discoveries 62128 2Researchers discover biological basis of bacterial immune system 10902 1Researchers discover biological basis of bacterial immune system 10902 2Researchers discover biological basis of bacterial immune system 10902 3Its not just dirt 21 10899 1Its not just dirt 21 10899 2
Other Biology News:Unmanned aerial vehicles mark robotic first for British Antarctic Survey 2Solving an avian scourge could also provide benefits to human health 2Solving an avian scourge could also provide benefits to human health 3Work with power grids leads to cell biology discovery 2Work with power grids leads to cell biology discovery 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |